65302-98-9

Basic information

• Product Name: Pentanoic acid, 2-hydroxy-4,4-dimethyl-
• CAS NO: 65302-98-9
• Molecular Formula: C7H14O3
• Molecular Weight: 146.186
• Mol File: 65302-98-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Pentanoic acid, 2-hydroxy-4,4-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanoic acid, 2-hydroxy-4,4-dimethyl-(65302-98-9)
• EPA Substance Registry System: Pentanoic acid, 2-hydroxy-4,4-dimethyl-(65302-98-9)

Safety Data

• Hazardous Substances Data: 65302-98-9(Hazardous Substances Data)

Upstream product

• 57224-50-7 (S)-2-Amino-4,4-dimethyl-pentanoic acid 
• 60122-72-7 4,4-Dimethyl-2(R)-aminopentanoic acid 
• 2987-16-8 3,3-dimethylbutyrylaldehyde 
• 65303-01-7 1-Chlor-4,4-dimethyl-1-phenylthio-2-pentanon 
• 65303-00-6 4,4-Dimethyl-1-phenylsulfinyl-2-pentanon 
• 65302-99-0 4,4-Dimethyl-1-phenylthio-2-pentanon 
• 29846-98-8 2-bromo-4,4-dimethylpentanoic acid 
• 65303-02-8 1-Acetoxy-4,4-dimethyl-1-phenylthio-2-pentanon 
• 4775-69-3 1-bromo-4,4-dimethylpentan-2-one 
• 65302-92-3 S-phenyl 2-acetoxy-4,4-dimethylpentanethioate 
• 65302-97-8 2-acetoxy-4,4-dimethylpentanoic acid 

Relevant articles and documents

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Inhibitors of prenyl-protein transferase

The present invention comprises unsubstituted and substituted piperazine-containing compounds having alkanoyl, alkylsulfonyl, alkylamido or alkoxycarbonyl substituents, and having the formula A, which inhibit prenyl-protein transferases. In particular, the invention relates to prenyl-protein transferase inhibitors which are efficacious in vivo as inhibitors of geranylgeranyl-protein transferase type I (GGTase-I) and that inhibit the cellular processing of both the H-Ras protein and the K4B-Ras protein. Such therapeutic compounds are useful in the treatment of cancer.